Published online before print November 14, 2002, doi: 10.1161/01.ATV.0000047448.76485.B8
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Serum Plasma Pregnancy-Associated Protein A
A Potential Marker of Echogenic Carotid Atherosclerotic Plaques in Asymptomatic Hyperlipidemic Subjects at High Cardiovascular Risk
From the Department of Clinical Biochemistry (J.-L.B., F.I.-B., M.B.), the National Institute for Health and Medical Research INSERM U551 (J.-L.B., P.G., E.B., M.J.C.), and the Department of Endocrinology and Metabolism (P.G., E.B.), Groupe Hospitalier Pitié-Salpêtrière (AP-HP), and the Department of Clinical Biochemistry (L.B.), Hôpital Robert Debré (AP-HP), Paris, France.
Correspondence to J.-L. Beaudeux, Department of Clinical Biochemistry C, Hôpital Pitié-Salpêtrière, 83 boulevard de l’Hôpital, F75651 Paris Cedex 13, France. E-mail jean-louis.beaudeux{at}psl.ap-hop-paris.fr
Objective— The proteolytic activity of metalloproteinases, proinflammatory enzymes that degrade extracellular matrix, is elevated in lipid-rich atherosclerotic plaques, thereby contributing to plaque fragility and rupture. Pregnancy-associated plasma protein (PAPP-A) is a metalloproteinase, expressed in unstable atherosclerotic plaques, whose circulating levels are elevated in acute coronary syndromes. We evaluated serum PAPP-A levels as a marker of the premature development of atherosclerosis in hyperlipidemic subjects at elevated cardiovascular risk.
Methods and Results— Serum PAPP-A levels were determined in asymptomatic hyperlipidemic male subjects (n=64; mean±SD age, 51±7 years) in whom intima-media thickness (IMT) and lesion status in the carotid artery were evaluated by noninvasive ultrasonography and compared with those of a normolipidemic control group (n=25). No difference was observed in circulating PAPP-A levels between hyperlipidemic subjects and controls (8.99±2.93 and 8.03±2.75 mIU/L, respectively; mean±SD) nor between hyperlipidemic subjects who presented with a luminal obstruction of the carotid artery (9.26±2.53 mIU/L) and those who did not (8.85±3.29 mIU/L). By contrast, in patients with atheromatous carotid plaques, a positive association between serum levels of PAPP-A and C-reactive protein was observed (P<0.05); moreover, subjects exhibiting hyperechoic or isoechoic, echogenic lesions had significantly higher PAPP-A levels compared with those with hypoechoic lesions (10.32±2.72 vs 8.27±2.18 mIU/L, P<0.05) and with normolipidemic controls (P<0.05).
Conclusions— Elevated serum PAPP-A levels represent a potential marker of the degree of echogenicity of carotid atherosclerotic plaques in asymptomatic hyperlipidemic patients at high cardiovascular risk and equally of an enhanced local inflammatory state involving remodeling of subendothelial extracellular matrix.
Key Words: pregnancy-associated plasma protein A • metalloproteinase • hyperlipidemia • carotid atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  S. Pellitero, J. L. Reverter, E. Pizarro, M. C. Pastor, M. L. Granada, D. Tassies, J.-C. Reverter, I. Salinas, and A. Sanmarti Pregnancy-Associated Plasma Protein-A Levels Are Related to Glycemic Control but Not to Lipid Profile or Hemostatic Parameters in Type 2 Diabetes Diabetes Care, December 1, 2007; 30(12): 3083 - 3085. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Onder, E. Capoluongo, M. Cesari, P. Lulli, R. Liperoti, B. Giardina, A. Russo, R. Bernabei, and F. Landi Association of Calcium Channel Blocker Use and Pregnancy-Associated Plasma Protein-A Among Older Adults With Hypertension: Results From the ilSIRENTE Study J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2007; 62(11): 1274 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wittfooth, Q.-P. Qin, J. Lund, I. Tierala, K. Pulkki, H. Takalo, and K. Pettersson Immunofluorometric Point-of-Care Assays for the Detection of Acute Coronary Syndrome-Related Noncomplexed Pregnancy-Associated Plasma Protein A Clin. Chem., September 1, 2006; 52(9): 1794 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Elesber, C. A. Conover, A. E. Denktas, R. J. Lennon, D. R. Holmes Jr, M. T. Overgaard, M. Christiansen, C. Oxvig, L. O. Lerman, and A. Lerman Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina Eur. Heart J., July 2, 2006; 27(14): 1678 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sangiorgi, A. Mauriello, E. Bonanno, C. Oxvig, C. A. Conover, M. Christiansen, S. Trimarchi, V. Rampoldi, D. R. Holmes Jr, R. S. Schwartz, et al. Pregnancy-Associated Plasma Protein-A Is Markedly Expressed by Monocyte-Macrophage Cells in Vulnerable and Ruptured Carotid Atherosclerotic Plaques: A Link Between Inflammation and Cerebrovascular Events J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2201 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Biasucci and V. Rizzello Pregnancy-associated plasma protein-a: do specific markers of vascular or plaque activation exist, and do we really need them? Clin. Chem., June 1, 2006; 52(6): 913 - 914. [Full Text] [PDF]
|
|
|
|
|
|
T. Mueller, B. Dieplinger, W. Poelz, and M. Haltmayer Increased Pregnancy-Associated Plasma Protein-A as a Marker for Peripheral Atherosclerosis: Results from the Linz Peripheral Arterial Disease Study Clin. Chem., June 1, 2006; 52(6): 1096 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heeschen, S. Dimmeler, S. Fichtlscherer, and A. M. Zeiher Reply J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1584 - 1585. [Full Text] [PDF]
|
|
|
|
|
|
J. Cosin-Sales, J. C. Kaski, M. Christiansen, P. Kaminski, C. Oxvig, M. T. Overgaard, D. Cole, and D. W. Holt Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris Eur. Heart J., October 2, 2005; 26(20): 2093 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome Clin. Chem., May 1, 2005; 51(5): 810 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heeschen, S. Dimmeler, C. W. Hamm, S. Fichtlscherer, M. L. Simoons, A. M. Zeiher, and CAPTURE Study Investigators Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: Comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis J. Am. Coll. Cardiol., January 18, 2005; 45(2): 229 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Chilton Pathophysiology of Coronary Heart Disease: A Brief Review J Am Osteopath Assoc, September 1, 2004; 104(9_suppl): 5S - 8S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cosin-Sales, M. Christiansen, P. Kaminski, C. Oxvig, M. T. Overgaard, D. Cole, D. W. Holt, and J. C. Kaski Pregnancy-Associated Plasma Protein A and Its Endogenous Inhibitor, the Proform of Eosinophil Major Basic Protein (proMBP), Are Related to Complex Stenosis Morphology in Patients With Stable Angina Pectoris Circulation, April 13, 2004; 109(14): 1724 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Naghavi, P. Libby, E. Falk, S. W. Casscells, S. Litovsky, J. Rumberger, J. J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, et al. From Vulnerable Plaque to Vulnerable Patient: A Call for New Definitions and Risk Assessment Strategies: Part II Circulation, October 14, 2003; 108(15): 1772 - 1778. [Abstract] [Full Text] [PDF]
|
|